Analytical Data
-
基因名
IGLV3-25
- Application
-
别名
IGLV3-25; Immunoglobulin lambda variable 3-25; Ig lambda chain V-IV region Hil
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P01717
-
表达区间
1-233aa
-
氨基酸序列
MAWIPLLLPLLTLCTGSEASYELTQPPSVSVSPGQTARITCSADALPKQYAYWYQQKPGQAPVLVIYKDSERPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCQSADTSGTYVVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
-
分子量
51.2 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Recombinant Human LAMa3 Protein，His
Cat：PA2000-217DB
Recombinant Human HOMER2 Protein，His
Cat：PA1000-1478
Protein Description
IGLV3-25, a member of the immunoglobulin lambda light chain gene family, has garnered attention in the field of immunology due to its role in the immune response and antibody diversity. The study of IGLV3-25 recombinant proteins is particularly relevant in understanding the mechanisms of B cell maturation and the processes leading to the production of antibodies that can effectively recognize and neutralize various pathogens. Recent advancements in biotechnology have enabled the recombinant expression of IGLV3-25 proteins, facilitating their use in various applications, including vaccine development, antibody engineering, and therapeutic interventions. Research indicates that specific mutations in the IGLV3-25 gene may enhance affinity and specificity towards certain antigens, making it a valuable target for engineering high-affinity antibodies. Furthermore, the insights gained from the structural characterization of IGLV3-25 can help decipher the intricate interactions between antibodies and their corresponding antigens. Overall, studies focused on IGLV3-25 recombinant proteins hold promise for innovative approaches in treating infectious diseases and improving vaccine efficacy.
